InsidersTradesSigma
基于 3 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Browse the detailed record of transactions filed by Gilead Sciences, Inc.. Director active across 5 companies, notably Arcus Biosciences, Inc.. In total, 11 reports have been published. Split: 9 buys · 0 sell. Total volume traded: €358.8m. Activity tracked since 27 June 2023. The latest transaction was filed on 26 May 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 条申报中的 11 条
GILEAD SCIENCES, INC. is a declarant with no primary role indicated. It has 11 filings in total, and in the sampled recent filings the transactions are mainly acquisitions, with buy or other transactions in Arcus Biosciences, Inc., Assembly Biosciences, INC. and Allovir, Inc. between 2023-06-28 and 2026-05-27.